• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Axogen Inc.

    11/7/24 4:34:48 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $AXGN alert in real time by email
    SC 13G 1 axgn_sc13g-110724.htm ACQUISITION OF BENEFICIAL OWNERSHIP

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934*

     

    Axogen, Inc

    (Name of Issuer)

     

    Common Stock, $0.01 par value

    (Title of Class of Securities)

     

    05463X106

    (CUSIP Number)

     

    October 31, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☒ Rule 13d-1(b)
         
      ☐ Rule 13d-1(c)
         
      ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    CUSIP No . 05463X106   Page 2 of 7

     

    1

    NAME OF REPORTING PERSONS
    First Light Asset Management, LLC

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY)

    46-3521994

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING POWER

    0

     
    6

    SHARED VOTING POWER

    4,364,858

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    4,364,858

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,364,858

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.96%

     
    12

    TYPE OF REPORTING PERSON

    IA

     
             

     

     
     

     

    CUSIP No . 05463X106   Page 3 of 7

     

    1

    NAME OF REPORTING PERSONS
    Mathew P. Arens

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY)

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United State of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING POWER

    0

     
    6

    SHARED VOTING POWER

    4,364,858

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    4,364,858

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,364,858

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.96%

     
    12

    TYPE OF REPORTING PERSON

    IN

     
             

     

     
     

     

    CUSIP No. 05463X106   Page 4 of 7

     

    Item 1(a).   Name of Issuer:
        AxoGen, Inc.
         
    Item 1(b).   Address of Issuer’s Principal Executive Offices:
        13631 Progress Boulevard, Suite 400, Alachua, FL 32615
         
    Item 2(a).   Name of Person Filing:
       

    This Schedule 13G is being jointly filed by the following:

     

    First Light Asset Management, LLC

    Mathew P. Arens (“Mr. Arens”)

       

     

    The Manager may be deemed to be the beneficial owner of 4,364,858 of the Issuer’s shares of common stock (the “Shares”). The Manager acts as an investment adviser to certain persons holding separately managed accounts with the Manager, each of whom has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, those shares. The Manager may also be deemed to be the beneficial owner of these shares because it acts as an investment adviser to certain private funds. Mr. Arens may also be deemed to be the beneficial owner of these shares because he controls the Manager in his position as managing member and majority owner of the Manager. The Manager and Mr. Arens are filing this Schedule 13G with respect to these Shares pursuant to Rule 13d-1(b) under the Act.

     

    The Manager and Mr. Arens may be deemed to be the beneficial owner of the total amount of Shares set forth across from its or his respective name in Item 4 below. The filing of this Schedule 13G shall not be construed as an admission that the reporting persons or any of their affiliates are the beneficial owner of any securities covered by this Schedule 13G for any other purposes other than Section 13(d) of the Securities Exchange Act of 1934.

         
    Item 2(b).   Address of Principal Business Office or, if None, Residence:
       

    Each of the reporting persons identified in Item 2(a) has its principal business office at:

     

    3300 Edinborough Way, Suite 201, Edina, MN 55435

         
    Item 2(c).   Citizenship:
       

    First Light Asset Management, LLC – Delaware limited liability company

    Mathew P. Arens – United States citizen

         
    Item 2(d).   Title of Class of Securities:
        Common Stock, $0.01 par value
         
    Item 2(e).   CUSIP Number:
        05463X106
         
    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☒ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

     
     

     

    CUSIP No . 05463X106   Page 5 of 7

     

      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☒ A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           
    Item 4. Ownership.
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       
      (a) Amount beneficially owned:
       

    First Light Asset Management, LLC – 4,364,858

    Mathew P. Arens – 4,364,858

         
      (b) Percent of class:
       

    First Light Asset Management, LLC – 9.96%

    Mathew P. Arens – 9.96%

     
         
      (c) Number of shares as to which such person has:
         
        (i) Sole power to vote or to direct the vote
         

    First Light Asset Management, LLC – 0

    Mathew P. Arens – 0

           
        (ii) Shared power to vote or to direct the vote
         

    First Light Asset Management, LLC – 4,364,858

    Mathew P. Arens – 4,364,858

           
        (iii) Sole power to dispose or to direct the disposition of
         

    First Light Asset Management, LLC – 0

    Mathew P. Arens – 0

           
        (iv) Shared power to dispose or to direct the disposition of
         

    First Light Asset Management, LLC – 4,364,858

    Mathew P. Arens – 4,364,858

     

     
     

     

    CUSIP No . 05463X106   Page 6 of 7

     

    Item 5. Ownership of Five Percent or Less of a Class.
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☐
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
      Not applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable
       
    Item 9. Notice of Dissolution of Group.
      Not applicable
       
    Item 10. Certification.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

     

      FIRST LIGHT ASSET MANAGEMENT, LLC
         
      Date: November 7, 2024  
           
      By: /s/ Kurt T. Peterson  
      Name: Kurt T. Peterson  
      Title: Chief Compliance Officer  
       
       
      Date: November 7, 2024  
           
      Signature: /s/ Mathew P. Arens  
      Name: Mathew P. Arens  

     

     
    Get the next $AXGN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AXGN

    DatePrice TargetRatingAnalyst
    3/17/2025$30.00Buy
    Lake Street
    7/1/2024$13.00Outperform
    Raymond James
    11/11/2022$15.00Buy
    Jefferies
    5/9/2022$10.00 → $15.00Hold → Buy
    Canaccord Genuity
    3/11/2022$21.00Overweight
    Cantor Fitzgerald
    11/4/2021$25.00 → $20.00Market Outperform
    JMP Securities
    More analyst ratings

    $AXGN
    SEC Filings

    View All

    SEC Form S-8 filed by Axogen Inc.

    S-8 - Axogen, Inc. (0000805928) (Filer)

    8/5/25 5:13:30 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Axogen Inc.

    10-Q - Axogen, Inc. (0000805928) (Filer)

    8/5/25 4:52:07 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Axogen, Inc. (0000805928) (Filer)

    8/5/25 7:02:14 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AXGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Axogen, Inc. Reports Second Quarter 2025 Financial Results

    ALACHUA, Fla. and TAMPA, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the second quarter ended June 30, 2025. Second Quarter Financial Results Second quarter revenue was $56.7 million, an 18.3% increase compared to the second quarter of 2024, and a 16.7% increase over the first quarter of 2025.For the second quarter of 2025, gross margin was 74.2%, up from 73.8% for the second quarter of 2024, and up from 71.9% in the first quarter of 2025.Net income for the quarter was $0.6

    8/5/25 7:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference

    ALACHUA, Fla. and TAMPA, Fla., July 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management will be available for one-on-one investor meetings at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. About Axogen Axogen (AXGN) is the leading Company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical

    7/29/25 4:10:00 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025

    ALACHUA, Fla. and TAMPA, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will report 2025 second quarter financial results on Tuesday, August 5, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the

    7/22/25 4:05:00 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AXGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Johnson John

    4 - Axogen, Inc. (0000805928) (Issuer)

    6/20/25 4:11:10 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Tyndall Joseph A.

    4 - Axogen, Inc. (0000805928) (Issuer)

    6/20/25 4:10:23 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Wendell Amy Mcbride

    4 - Axogen, Inc. (0000805928) (Issuer)

    6/20/25 4:09:51 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AXGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on AxoGen with a new price target

    Lake Street initiated coverage of AxoGen with a rating of Buy and set a new price target of $30.00

    3/17/25 8:23:19 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Raymond James initiated coverage on AxoGen with a new price target

    Raymond James initiated coverage of AxoGen with a rating of Outperform and set a new price target of $13.00

    7/1/24 7:31:31 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Jefferies resumed coverage on AxoGen with a new price target

    Jefferies resumed coverage of AxoGen with a rating of Buy and set a new price target of $15.00

    11/11/22 9:07:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AXGN
    Leadership Updates

    Live Leadership Updates

    View All

    Axogen Announces Chief Financial Officer Transition

    ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Lindsey Hartley, CPA, as Chief Financial Officer, effective May 12, 2025. Ms. Hartley, who currently serves as Vice President, Corporate Controller at Axogen, will succeed Nir Naor, who is departing to pursue other opportunities. Mr. Naor will remain with the Company in an advisory capacity until July 1, 2025, to ensure a smooth transition. "I want to express my sincere gratitude to Nir for his service to Axogen," said Michael Dale, President, Chief Executive O

    5/8/25 7:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    ALACHUA, Fla. and TAMPA, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy. Mr. Ditto will report to Michael Dale, President, and Chief Executive Officer, and will lead the development of the coverage and reimbursement-related strategies required to support Axogen's mission to establish restoration of peripheral nerve function as an expected standard of care. Mr. Ditto brings over 15 years of leadership experience in the medical device industry, with a pr

    3/24/25 8:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    ALACHUA, Fla. and TAMPA, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Jesse Bishop as Vice President of Regulatory Affairs. Mr. Bishop will report to Michael Dale, President, and Chief Executive Officer, and will lead the development and execution of domestic and international regulatory strategies to advance company objectives related to new product development, market approval, market development and other regulatory initiatives. Mr. Bishop will oversee all facets of Axogen's regulatory affairs, maintenance of Axogen product

    2/3/25 8:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AXGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Axogen Inc.

    SC 13G/A - Axogen, Inc. (0000805928) (Subject)

    11/14/24 3:31:14 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Axogen Inc.

    SC 13G - Axogen, Inc. (0000805928) (Subject)

    11/7/24 4:34:48 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Axogen Inc.

    SC 13G/A - Axogen, Inc. (0000805928) (Subject)

    9/10/24 4:00:03 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AXGN
    Financials

    Live finance-specific insights

    View All

    Axogen, Inc. Reports Second Quarter 2025 Financial Results

    ALACHUA, Fla. and TAMPA, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the second quarter ended June 30, 2025. Second Quarter Financial Results Second quarter revenue was $56.7 million, an 18.3% increase compared to the second quarter of 2024, and a 16.7% increase over the first quarter of 2025.For the second quarter of 2025, gross margin was 74.2%, up from 73.8% for the second quarter of 2024, and up from 71.9% in the first quarter of 2025.Net income for the quarter was $0.6

    8/5/25 7:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025

    ALACHUA, Fla. and TAMPA, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will report 2025 second quarter financial results on Tuesday, August 5, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the

    7/22/25 4:05:00 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen, Inc. Reports 2025 First Quarter Financial Results

    ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2025. First Quarter Financial Results First quarter revenue was $48.6 million, a 17.4% increase compared to the first quarter of 2024.For the first quarter of 2025, gross margin was 71.9%, down from 78.8% for the first quarter of 2024.Net loss for the quarter was $3.8 million, or $0.08 per share, compared to $6.6 million, or $0.15 per share for the first quarter of 2024.Adjusted net loss for the quart

    5/8/25 7:05:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care